Abstracts tagged "anti-citrullinated protein/peptide antibodies (ACPA)"

Abstract Number: 145 • 2020 Pediatric Rheumatology Symposium
Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA
Saumya Joshi¹, Yujuan Zhang ¹ and Trevor Davis ², ¹Tufts Medical Center, Boston, Massachusetts, ²Norwell, Massachusetts
Background/Purpose: Despite being a well-established biomarker for classification of aggressive bony disease in adults with RA, ACPA have not yet been described in the ILAR…
Abstract Number: 496 • 2019 ACR/ARP Annual Meeting
Assessment of Anti-Cyclic Citrullinated Protein and Connective Tissue Disease Screening Questionnaire in Healthy Adults from the Oklahoma Immune Cohort
McKayla Muse¹, Ly Tran ¹, Carla J. Guthridge ², Nancy Redinger ² and Judith James ³, ¹Oklahoma Medical Research Foundation, Oklahoma City, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Anti-CCP antibodies are present in the serum of healthy individuals who are at risk of developing RA and serve as an important tool for…
Abstract Number: 546 • 2019 ACR/ARP Annual Meeting
Change in Rheumatoid Arthritis (RA)-Related Autoantibody Profile and Risk of Disease Flare After Withdrawal of Therapy in Patients with Early RA Treated with Abatacept and MTX
René Toes¹, Thomas Lehman ², Joshua Bryson ³, Amy Min Kim ², Sandhya Balachandar ², Sumanta Mukherjee ², Michael Maldonado ², Sean Connolly ² and Thomas Huizinga ¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Bristol-Myers Squibb, Princeton, NJ, ³Bristol-Myers Squibb, Princeton
Background/Purpose: An emerging concept of “immunologic remission” in RA raises questions about the relevance of the RA autoantibody profile in patients (pts) who are otherwise…
Abstract Number: 987 • 2019 ACR/ARP Annual Meeting
Anti-citrullinated Protein Antibodies Induce Subclinical Inflammation, Bone Loss and Pain in Mice
Akilan Krishnamurthy¹, Yogan Kisten ², Alexandra Circiumaru ³, Katalin Sandor ⁴, Koji Sakurabas ⁵, Gustaf Wigerblad ⁶, Peter Damberg ⁷, Heidi Wähämaa ³, Patrik Jarvolli ⁷, Vivianne Malmström ⁸, Lars Klareskog ⁹, Camilla I Svensson ¹⁰, Juan Jimenez Jimenez Andrade ¹¹, Bence Rethi ³ and Anca Catrina ⁹, ¹Rheumatology unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Solna, Stockholm, ²Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, ⁴Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden, stockholm, Sweden, ⁵Rheumatology unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Solna, stockholm, Sweden, ⁶karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁷Karolinska Institutet, Karolinska Experimental Research and Imaging Centre (KERIC), stockholm, Sweden, stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁹Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ¹⁰Karolinska Institutet, Physiology and Pharmacology, stockholm, Sweden, Stockholm, Sweden, ¹¹Universidad Autónoma de Tamaulipas, Reynosa, Tamaulipas, Mexico, Tamaulipas, Mexico
Background/Purpose: Autoantibodies against citrullinated proteins (ACPAs) could be associated with bone loss, pain and tenosynovitis prior to disease onset in human rheumatoid arthritis (RA) and…
Abstract Number: 994 • 2019 ACR/ARP Annual Meeting
Increased Antibody and T-cell Responses Following Treatment of Collagen-Induced Arthritis in C57Bl/6 Mice with Organic Dust Inhalants
Michael Duryee¹, Jill Poole ¹, Amy Nelson ¹, Katherine Janike ¹, Kathryn Rentfro ¹, Lynell Klassen ¹, James O'Dell ², Bryant England ³, Geoffrey Thiele ² and Ted Mikuls ², ¹University of Nebraska Medical Center, Omaha, NE, ²VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ³VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha
Background/Purpose: Increasing evidence suggests that inhalant exposures, such as tobacco smoke or silica, are implicated in the initiation of autoimmunity leading to rheumatoid arthritis (RA).…
Abstract Number: 1758 • 2019 ACR/ARP Annual Meeting
Development of Ultrasound Detectable Arthritis Among ACPA Positive Subjects with Musculoskeletal Symptoms: The Risk RA Prospective Study
Aase Hensvold¹, Yogan Kisten ², Alexandra Circiumaru ¹, Monika Hansson ³, Meng Sun ¹, Guozhong Fei ⁴, Nancy Vivar ², Erik af Klint ², Hamed Rezaei ², Lars Klareskog ³, Aleksandra Antovic ⁵ and Anca Catrina ³, ¹Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, ²Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁴Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Sweden, ⁵Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Studies have shown that anti-citrullinated protein antibodies (ACPA) are a risk factor for the development of arthritis. We aimed to investigate in a prospective…
Abstract Number: 1886 • 2019 ACR/ARP Annual Meeting
Antibody Systems Targeting Citrullinated, Carbamylated, and Peptidyl Arginine Deaminase Autoantigens Distinguish Rheumatoid Arthritis in Combination with Rheumatoid Factors
Thierry Dervieux¹, Joel Kremer ², John Conklin ¹, Kelley Brady ¹, Roberta Alexander ¹, Tyler O'Malley ³, Jing Shi ¹, Claudia Ibarra ¹, Michael Mahler ⁴, Michael Weinblatt ⁵ and Arthur Weinstein ¹, ¹Exagen, Vista, CA, ²Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY, ³Exagen, Oceanside, CA, ⁴Inova Diagnostics, San Diego, CA, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: Novel antibody systems including anti-carbamylated protein antibody (anti-CarP IgG) and anti-peptidyl arginine deiminase antibody (anti-PAD4 IgG) are emerging as independent diagnostic and prognostic biomarkers…
Abstract Number: 2861 • 2019 ACR/ARP Annual Meeting
Lung-Related Factors Are Associated with Transitions from Systemic Anti-CCP Antibody Positivity to Classified RA
Ashley Visser ¹, Marie Feser ², Chelsie Fleischer ³, Laura Lenis-Charry ¹, Justin August ¹, Elizabeth Bemis ⁴, Jill Norris ⁵, V. Michael Holers ⁶, Kevin Deane ² and M. Kristen Demoruelle⁷, ¹University of Colorado Denver, Aurora, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, ⁴University of Colorado Denver, School of Public Health, Aurora, CO USA, Aurora, ⁵Colorado School of Public Health, Aurora, ⁶University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁷University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora
Background/Purpose: Systemic autoimmunity associated with RA precedes the onset of inflammatory arthritis (IA) by several years. In particular, the presence of systemic anti-cyclic citrullinated peptide…
Abstract Number: 16 • 2019 ACR/ARP Annual Meeting
Monoclonal ACPA Promote Synovial Fibroblasts Migration Through a Peptidylarginine Deiminases (PAD) Dependent Pathway
Meng Sun¹, Bence Rethi ¹, Akilan Krishnamurthy ², Vijay Joshua ³, Alexandra Circiumaru ¹, Aase Hensvold ¹, Marianne Engström ⁴, Sergiu-Bogdan Catrina ⁵, Johanna Steen ⁶, Vivianne Malmström ³, Caroline Grönwall ³, Lars Klareskog ⁷, Heidi Wähämaa ¹ and Anca Catrina ⁷, ¹Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, ²Rheumatology unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Solna, Stockholm, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁴Karolinska Institutet and Karolinska University Hospital, Stockholm, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Stockholm University, Stockholm, ⁷Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) play an important role in rheumatoid arthritis (RA) pathogenesis. ACPAs have different amino acid motif recognition patterns and show cross-reactivity…
Abstract Number: 47 • 2019 ACR/ARP Annual Meeting
Autoreactivity to Acetylated Histones Defines a Subset of RA Patients and Is Associated with Acetyl – Citrulline Anti-Modified Protein Autoantibody (AMPA) Cross-Reactivity
Peter Sahlström ¹, Lisa Liljefors ¹, Vijay Joshua ², Natalia Sherina ¹, Radha Thyagarajan ¹, Lena Israelsson ², Ragnhild Stålesen ², Monika Hansson ³, Khaled Amara ², Ulf Reimer ⁴, Leonid Padyukov ¹, Elisabet Svenungsson ⁵, Karin Lundberg ¹, Anca Catrina ³, Lars Klareskog ³, Vivianne Malmström ² and Caroline Grönwall², ¹Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, ³Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁴JPT Peptide Technologies, Berlin, Germany, ⁵Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Serum anti-citrullinated protein autoantibodies (ACPA) in rheumatoid arthritis (RA) display reactivity to a variety of cit-autoantigens. Studies of human ACPA mAbs have revealed that…
Abstract Number: 249 • 2019 ACR/ARP Annual Meeting
Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity
Damemarie Paul ¹, Xue Han², Irina Yermilov ³, Sarah Gibbs ³ and Michael Broder ³, ¹Bristol-Myers Squibb, Lawrenceville, NJ, ²Bristol-Myers Squibb Company, Princeton, NJ, ³Partnership for Health Analytic Research, LLC, Beverly Hills, CA
Background/Purpose: Abatacept is recommended as first-line biologic therapy in adult patients with moderate to severe RA. We aimed to assess real-world 1-year treatment persistence in…
Abstract Number: 450 • 2019 ACR/ARP Annual Meeting
ACPA-positive versus ACPA-negative Rheumatoid Arthritis: Two Distinct Erosive Disease Entities on Radiography and Ultrasonography
Julien Grosse¹, Edem Allado ¹, Camille Roux ¹, Audrey Pierreisnard ², Marion Couderc ³, Isabelle Clerc-Urmès ¹, Thomas Remen ¹, Eliane Albuisson ⁴, Marcelo De Carvalho ¹, Isabelle Chary-Valckenaere ⁴ and Damien Loeuille ⁵, ¹Centre Hospitalier Universitaire de Nancy, Nancy, France, ²APHP, Paris, France, ³CHU G.Montpied, Clermont Ferrand, France, ⁴Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, ⁵Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France
Background/Purpose: Several studies have shown that ACPA-positive (ACPA+) patients were more likely to develop erosive disease on radiography (RX) than ACPA-negative (ACPA-) patients, but it…
Abstract Number: 455 • 2019 ACR/ARP Annual Meeting
Anti-Protein-Arginine Deiminase (PAD) 4 IgA Are Present in the Sera of Rheumatoid Arthritis Patients and Are Associated with Joint Erosion and Biological Treatment Use
Laura Martinez-Prat¹, Victor Manuel Martínez Taboada ², Marcos Lopez-Hoyos ³ and Michael Mahler ⁴, ¹Inova Diagnostics, Francisco de Vitoria University, San Diego, CA, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Cantabria, Spain, ⁴Inova Diagnostics, San Diego, CA
Background/Purpose: Over the past years, novel biomarkers have been described in rheumatoid arthritis (RA) patients, including autoantibodies to the protein-arginine deiminase (PAD) enzymes. Anti-PAD4 IgG…
Abstract Number: 482 • 2019 ACR/ARP Annual Meeting
Antibody Repertoire Sequencing, Antigen Array Analysis, and Cytokine Profiling of Blood from Individuals at High-risk for RA Reveals Candidate Immunoglobulin V Genes, ACPA, and Cytokines That May Promote the Transition to Arthritis
Radhika Iyer¹, Amin Zia ¹, Michelle Bloom ¹, Sunil Nagpal ², Navin Rao ², Frédéric Baribaud ³, George Vratsanos ⁴, Wei Wang ⁵, Gary Firestein ⁶, David Boyle ⁵, Jane Buckner ⁷, V. Michael Holers ⁸, Kevin Deane ⁹ and William Robinson ¹⁰, ¹Stanford University, Stanford, ²Janssen R&D, Spring House, PA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴JNJ, Raritan, NJ, ⁵University of California, San Diego, San Diego, CA, ⁶University of California, San Diego, San Diego, ⁷Benaroya Research Institute, Seattle, WA, ⁸University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁹University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ¹⁰Stanford University, Stanford, CA
Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated…
Abstract Number: 19 • 2018 ACR/ARHP Annual Meeting
Citrulline-Multispecific B Cell Receptor Clades in Rheumatoid Arthritis
Philip J. Titcombe^1,2, Natalie Sippl³, Monika Hansson⁴, Lena Israelsson³, Khaled Amara³, Timothy B. Niewold⁵, Lars Klareskog², Vivianne Malmström² and Daniel L. Mueller⁶, ¹The Center for Immunology, Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ²Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Colton Center for Autoimmunity, New York University, New York, NY, ⁶Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) have proven highly useful as biomarkers in rheumatoid arthritis (RA) and appear to be important to disease pathogenesis. Nevertheless, the…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].